• LAST PRICE
    0.0760
  • TODAY'S CHANGE (%)
    Trending Up0.0012 (1.6722%)
  • Bid / Lots
    0.0715/ 620
  • Ask / Lots
    0.0780/ 452
  • Open / Previous Close
    0.0715 / 0.0748
  • Day Range
    Low 0.0715
    High 0.0760
  • 52 Week Range
    Low 0.0500
    High 0.5395
  • Volume
    17,884
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.07475
TimeVolumeARDS
09:32 ET16750.0715
10:01 ET150000.07345
11:08 ET4000.074
01:44 ET1580.076
02:09 ET3000.076
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesARDS
Aridis Pharmaceuticals Inc
3.3M
-0.4x
---
United StatesANTI
Antigenics Inc
2.4K
0.0x
---
United StatesAQB
AquaBounty Technologies Inc
7.7M
-0.3x
---
United StatesRAYT
Rayont Inc
50.0
0.0x
---
United StatesHSTO
Histogen Inc
1.7M
-0.1x
---
United StatesENSC
Ensysce Biosciences Inc
2.5M
-0.2x
---
As of 2024-03-28

Company Information

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.

Contact Information

Headquarters
983 University Avenue, Bldg. BLOS GATOS, CA, United States 95032
Phone
408-385-1742
Fax
408-960-3822

Executives

Co-Founder, Executive Chairman of the Board
Eric Patzer
Chief Executive Officer, Co-Founder, Chief Scientific Officer, Director
Vu Truong
Chief Medical Officer
Hasan Jafri
Independent Director
John Hamilton
Independent Director
Susan Windham- Bannister

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.3M
Revenue (TTM)
$22.4M
Shares Outstanding
44.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.99
EPS
$-0.18
Book Value
$-0.90
P/E Ratio
-0.4x
Price/Sales (TTM)
0.1
Price/Cash Flow (TTM)
---
Operating Margin
-3.95%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.